IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT04086264

Public ClinicalTrials.gov record NCT04086264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML.

Study identification

NCT ID: NCT04086264
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: AbbVie; Industry
Enrollment: 218 participants

Conditions and interventions

Conditions

Acute Myeloid Leukemia

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 6, 2019 (Actual)
Primary completion: Feb 2027 (Estimated)
Completion: Feb 2027 (Estimated)
Last update posted: Aug 14, 2025

2019 – 2027

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
City of Hope National Medical Center /ID# 269273	Duarte	California	91010	—
University Of California Irvine Medical Center /ID# 269275	Orange	California	92868	—
Moffitt Cancer Center /ID# 269269	Tampa	Florida	33612	—
Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 269642	Chicago	Illinois	60611-3015	—
Dana-Farber Cancer Institute /ID# 269267	Boston	Massachusetts	02215	—
University of Michigan /ID# 269079	Ann Arbor	Michigan	48109-2800	—
Mayo Clinic Hospital Rochester /ID# 269643	Rochester	Minnesota	55905	—
Roswell Park Cancer Institute /ID# 269266	Buffalo	New York	14263	—
New York Presbyterian Hospital Weill Cornell Medical Center /ID# 269271	New York	New York	10461	—
Duke University Health System /ID# 269268	Durham	North Carolina	27705-3976	—
Cleveland Clinic - Cleveland /ID# 269272	Cleveland	Ohio	44195	—
MD Anderson Houston /ID# 269265	Houston	Texas	77030-4000	—
Fred Hutchinson Cancer Research Center /ID# 269270	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04086264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 14, 2025 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04086264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →